keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C genotype 3

keyword
https://www.readbyqxmd.com/read/28225572/daclatasvir-and-asunaprevir-for-genotype-1b-chronic-hepatitis-c-patients-with-chronic-kidney-disease
#1
Chisa Kondo, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Toru Asano, Kai Yoshizawa, Tomomi Okubo, Yoshimichi Chuganji, Yoshio Aizawa, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
AIM: To evaluate the efficacy and safety of daclatasvir and asunaprevir combined therapy in genotype 1b chronic hepatitis C (CHC) patients with non-dialysis chronic kidney disease (CKD). METHODS: In a multicenter collaborative study, 249 patients received 60 mg of daclatasvir (NS5A inhibitor) once a day and 100 mg of asunaprevir (NS3/4A protease inhibitor) twice a day for 24 weeks between September 2014 and September 2015 and were subjected to this analysis...
February 22, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28224025/lack-of-association-between-interleukin-28b-gene-polymorphisms-rs8099917g-t-rs12979860-c-t-and-susceptibility-to-chronic-hepatitis-c-virus-infection-tehran-iran
#2
Maryam Karkhane, Seyed Reza Mohebbi, Pedram Azimzadeh, Mahsa Saeedi Niasar, Mohamad Reza Sarbazi, Afsaneh Sharifian, Afshin Mohammad Alizadeh
AIM: Chronic Hepatitis C infection is a critical health problem worldwide, which caused by hepatitis C virus (HCV). Interleukin 28B (IL28B) is a determinant factor in disease progression and also susceptibility to chronic HCV infection. BACKGROUND: The most significant aim of this study is to analyze the association between IL28B gene polymorphisms with susceptibility to chronic HCV infection in Iranian population. METHODS: This study follows a case- control study design, in which, 288 patients with chronic hepatitis C and 250 healthy individuals were genotyped for IL28B polymorphisms (rs12979860 C/T and rs8099917 G/T)...
December 2016: Gastroenterology and Hepatology From Bed to Bench
https://www.readbyqxmd.com/read/28220833/early-hepatitis-b-surface-antigen-decline-predicts-treatment-response-to-entecavir-in-patients-with-chronic-hepatitis-b
#3
Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen
Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined significantly in both groups at Month 3, but only at Months 6-12 in the HBeAg-negative group. Both groups exhibited a significant HBsAg decline with each successive year of treatment...
February 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28217259/phase-3-trial-of-first-generation-protease-inhibitor-therapy-for-hepatitis-c-virus-human-immunodeficiency-virus-coinfection
#4
Kenneth E Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Jennifer J Kiser, Beverly Alston-Smith, Wayne Greaves, Adeel A Butt, The Actg Birth Study Team
AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and boceprevir, with a PEG-IFN/RBV lead-in phase was performed. The HCV/human immunodeficiency virus coinfected study population included treatment naïve (TN) and treatment experienced (TE) patients...
February 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28217256/interferon-free-regimens-in-patients-with-hepatitis-c-infection-and-renal-dysfunction-or-kidney-transplantation
#5
REVIEW
Evangelos Cholongitas, Chrysoula Pipili, George V Papatheodoridis
Treatment of patients with chronic kidney disease (CKD) and chronic hepatitis C (CHC) differs from that used in the general CHC population mostly when glomerular filtration rate (GFR) is below 30 mL/min, as sofosbuvir, the backbone of several current regimens, is officially contraindicated. Given that ribavirin free regimens are preferable in CKD, elbasvir/grazoprevir is offered in CHC patients with genotype 1 or 4 and ombitasvir/paritaprevir and dasabuvir in genotype 1b for 12 wk. Although regimens containing peginterferon with or without ribavirin are officially recommended for patients with CKD and genotype 2, 3, 5, 6, such regimens are rarely used because of their low efficacy and the poor safety and tolerance profile...
February 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28214980/sil2r-ratio-as-early-marker-for-response-in-hairy-cell-leukemia-and-the-prognostic-relevance-of-il28b-genotype-to-interferon-%C3%AE-therapy
#6
Stéphanie Jud, Jeroen S Goede, Oliver Senn, Katharina Spanaus, Markus G Manz, Rudolf Benz
Interferon-α (IFNα) was the first effective drug therapy for hairy cell leukemia (HCL). Nowadays, it is used as an alternative treatment in selected patients. Due to unlimited treatment time, monitoring and early prediction of response are important. Moreover, IFNα is used in the therapy of chronic hepatitis C, where a single nucleotide polymorphism of interleukin-28B gene (IL28B) correlates with therapy response. The role of this polymorphism in therapy response of IFNα-treated patients with HCL is unknown...
February 18, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28202798/high-prevalence-and-diversity-of-hepatitis-viruses-in-suspected-cases-of-yellow-fever-in-the-democratic-republic-of-congo
#7
Sheila Makiala-Mandanda, Frédéric Le Gal, Nadine Ngwaka-Matsung, Steve Ahuka-Mundeke, Richard Onanga, Berthold Bivigou-Mboumba, Elisabeth Pukuta-Simbu, Athenaïs Gerber, Jessica L Abbate, Dieudonné Mwamba, Nicolas Berthet, Eric Maurice Leroy, Jean-Jacques Muyembe-Tamfum, Pierre Becquart
The majority of patients with acute febrile jaundice (>95%) identified through a yellow fever surveillance program in the Democratic Republic of Congo (DRC) test negative for antibodies against yellow fever virus. However, no etiological investigation has ever been carried out on these patients. Here, we tested for hepatitis A (HAV), B (HBV), C (HCV), D (HDV) and E (HEV) viruses, all of which can cause acute febrile jaundice, in patients included in the yellow fever surveillance program in the DRC. On a total of 498 serum samples collected from suspected cases of yellow fever from January 2003 to January 2012, ELISA techniques were used to screen for antibodies against HAV (IgM) and HEV (IgM) and for antigens and antibodies against HBV (HBsAg and anti-HBc IgM), HCV and HDV...
February 15, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28198546/a-molecular-epidemiology-study-investigating-familial-clustering-of-hepatitis-b-virus-infection-in-families-with-unfavorable-prognoses-in-northwest-china
#8
Yuan Yang, Dan Du, Li Jin, Zhen Tian, Qian Li, Ruitian Yi, Ting Qiu, Daokun Yang, Yingli He, Jinfeng Liu, Tianyan Chen, Yingren Zhao
Hepatitis B virus (HBV) infections and adverse outcome have been demonstrated to show characteristics of familial clustering. The aim of this study was to investigate the prevalence of different HBV genotypes, HBV sub-genotypes, and Pre-S mutations associated with familial HBV infection clusters with unfavorable prognoses. Families presenting with clustered HBV infections and unfavorable prognoses were enrolled in this study. Non-clustered HBV-infected individuals were used as the control group. DNA extracted from patient serum samples was used to facilitate characterization of the HBV genotypes, HBV sub-genotypes, and Pre-S mutations by phylogenetic analysis...
February 15, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28197802/effects-of-vaccine-acquired-polyclonal-anti-hbs-antibodies-on-the-prevention-of-hbv-infection-of-non-vaccine-genotypes
#9
Masaki Kato, Susumu Hamada-Tsutsumi, Chiaki Okuse, Aiko Sakai, Nobuyuki Matsumoto, Masaaki Sato, Toshiyuki Sato, Mitsumi Arito, Kazuki Omoteyama, Naoya Suematsu, Kazuki Okamoto, Takanobu Kato, Fumio Itoh, Ryo Sumazaki, Yasuhito Tanaka, Hiroshi Yotsuyanagi, Tomohiro Kato, Manae Suzuki Kurokawa
BACKGROUND: In universal hepatitis B (HB) vaccination, single vaccine-derived polyclonal anti-HBs antibodies (anti-HBs) need to inhibit infection of HB viruses (HBV) of non-vaccine genotypes. We experimentally addressed this issue. METHODS: Anti-HBs-positive sera were obtained by vaccination with genotype A- or C-derived HBs antigen (HBsAg, gtA-sera or gtC-sera). Their reactivity to genotype A- and C-derived HBsAg (gtA-Ag and gtC-Ag) was measured by ELISA. The capacity of sera to neutralize HBV was evaluated using an in vitro infection model...
February 14, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28193518/safety-and-efficacy-of-elbasvir-grazoprevir-in-patients-with-hepatitis-c-virus-infection-and-compensated-cirrhosis-an-integrated-analysis
#10
Ira M Jacobson, Eric Lawitz, Paul Y Kwo, Christophe Hézode, Cheng-Yuan Peng, Anita Y M Howe, Peggy Hwang, Janice Wahl, Michael Robertson, Eliav Barr, Barbara A Haber
BACKGROUND & AIMS: Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials. METHODS: We performed an integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials...
February 10, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28192235/high-hcv-subtype-heterogeneity-in-a-chronically-infected-general-population-revealed-by-high-resolution-hcv-subtyping
#11
Francisco Rodriguez-Frias, Leonardo Nieto, Josep Gregori, Damir Garcia-Cehic, Rosario Casillas, David Tabernero, Maria Homs, Maria Blasi, Marta Vila, Qian Chen, Victor Vargas, Lluís Castells, Lluís Viladomiu, Joan Genesca, Beatriz Minguez, Salvador Augustin, Judit Carbonell, Celia Perales, Maria Eugenia Soria, Miriam Asensio, Meritxell Llorens, Laura Ordeig, Cristina Godoy, Maria Buti, Rafael Esteban, Tomas Pumarola, Juan Ignacio Esteban, Josep Quer
OBJECTIVES: Accurately characterize the chronically-infected general HCV population in the Barcelona area by a highly sensitive subtyping method able to identify the 67 recognized hepatitis C virus (HCV) subtypes, and to discriminate mixed infections in a single individual. This information has strong implications on patient management, in deciding the optimal combination of direct-acting antivirals (DAAs) for each patient. METHODS: HCV subtyping by UDPS. All HCV patients who attended Vall d'Hebron Hospital outpatient clinics from February 2015 to May 2016 (N=1473) were included...
February 10, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28191658/interpatient-mutational-spectrum-of-human-coronavirus-oc43-revealed-by-illumina-sequencing
#12
Geoffrey J Gorse, Gira B Patel, Xiaofeng Fan
Human coronaviruses (HCoV) are RNA viruses that cause respiratory tract infections with viral replication of limited duration. The host and viral population heterogeneity could influence clinical phenotypes. Employing long RT-PCR with Illumina sequencing, we quantified the gene mutation load at 0.5% mutation frequency for the 4,529 bp-domain spanning the Spike gene (4,086 bp) of HCoV-OC43 in four upper respiratory clinical specimens obtained during acute illness. There were a total of 121 mutations for all four HCoV samples with the average number of mutations at 30...
February 12, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/28187879/validated-stability-indicating-hplc-dad-method-for-determination-of-the-recently-approved-hepatitis-c-antiviral-agent-daclatasvir
#13
M M Baker, D S El-Kafrawy, M S Mahrous, T S Belal
A comprehensive stability indicating HPLC with diode array detection method was developed for the determination of the recently approved antiviral drug daclatasvir dihydrochloride (DCV) which is used for the treatment of chronic Hepatitis C Virus (HCV) genotype 3 infection. Effective chromatographic separation was achieved using Waters C8 column (4.6×250mm, 5μm particle size) with isocratic elution of the mobile phase composed of mixed phosphate buffer pH 2.5 and acetonitrile in the ratio of 75:25 (by volume)...
February 7, 2017: Annales Pharmaceutiques Françaises
https://www.readbyqxmd.com/read/28187751/efficacy-safety-and-pharmacokinetics-of-simeprevir-and-tmc647055-ritonavir-with-or-without-ribavirin-and-jnj-56914845-in-hcv-genotype-1-infection
#14
RANDOMIZED CONTROLLED TRIAL
Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M Schattenberg, Peter Buggisch, Sven Francque, Leen Vijgen, Thomas N Kakuda, Eva Hoeben, Donghan Luo, An Vandebosch, Bert Jacquemyn, Pieter Van Remoortere, René Verloes
BACKGROUND: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naïve and prior-relapse patients. METHODS: The study comprised four 12-week treatment panels: Panel 1 (n = 10; GT1a) and Panel 2-Arm 1 (n = 12; GT1b): simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day; Panel 2-Arm 2 (n = 9; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1: n = 22; GT1a/GT1b) or 60 mg once daily (Arm 2: n = 22; GT1a/GT1b)...
February 10, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28184998/natural-history-of-chronic-hepatitis-b-virus-infection-in-children-in-japan-a-comparison-of-mother-to-child-transmission-with-horizontal-transmission
#15
Tomoko Takano, Hitoshi Tajiri, Satoyo Hosono, Ayano Inui, Jun Murakami, Kosuke Ushijima, Yoko Miyoshi, Yuri Etani, Daiki Abukawa, Mitsuyoshi Suzuki, Stephen Brooks
BACKGROUND: It is necessary to evaluate the natural history of children with hepatitis B virus (HBV) infection in each country to consider their long-term management. METHODS: A multi-center observational study of children with chronic HBV infection who were diagnosed at age ≤15 years was carried out in 18 hospitals in Japan. RESULTS: We reviewed children with HBV infection including 381 with mother-to-child transmission (MTCT) and 154 with horizontal transmission, genotype C being the most prevalent virus genotype (83%)...
February 9, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28182307/chronologic-changes-of-serum-hepatitis-b-virus-dna-genotypes-surface-antigen-mutants-and-reverse-transcriptase-mutants-during-25-year-nationwide-immunization-in-taiwan
#16
Hong-Yuan Hsu, Mei-Hwei Chang, Yen-Hsuan Ni, Cheng-Lun Chiang, Jia-Feng Wu, Huey-Ling Chen, Pei-Jer Chen, Ding-Shinn Chen
We investigated breakthrough infection and hepatitis B virus (HBV) genetic changes in immunized subjects after 25-year of a universal infant immunization. Specifically, serum HBV DNA, genotypes, surface antigen mutants and nucleoside analog-resistant (NAr) mutants were assessed in 2853 subjects (<25-years-old) surveyed in 2009, and these data were compared with the data from previous serosurveys. A comparison across different age-stratified groups using the 2009 data revealed a significant increase in the seropositive rate of anti-HBc (5...
February 9, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28181035/complete-genome-sequence-of-a-hepatitis-b-virus-isolate-of-genotype-d2-subtype-adrq-from-brazil
#17
Natália Spitz, Aline S Moreira, Francisco C A Mello, Helena Cristina F Franz, Selma A Gomes, Natalia M Araujo
Hepatitis B virus (HBV) has been classified into 10 distinct serological subtypes of the surface antigen (HBsAg) that can be predicted by sequencing of the corresponding S gene. HBV genotype D usually displays determinants of subtypes ayw2 or ayw3. On the other hand, subtype adrq+ has been found exclusively in association with genotype C. Here, we describe the first HBV genome (isolate BR32) belonging to genotype D with the serological subtype adrq+. This isolate had a genome length of 3,062 nucleotides (nt), and no recombination events were observed in the BR32 genome that could explain the occurrence of the subtype adr in a genotype D isolate...
February 8, 2017: Archives of Virology
https://www.readbyqxmd.com/read/28179602/the-safety-profile-of-telaprevir-based-triple-therapy-in-clinical-practice-a-retrospective-cohort-study
#18
Ryo Iketani, Kazuki Ide, Hiroshi Yamada, Yohei Kawasaki, Naohiko Masaki
This study was designed to evaluate the safety profile of adding telaprevir to therapy using pegylated interferon-alfa-2b and ribavirin (PR) using real world patient data obtained from a nationwide Japanese interferon database. This retrospective cohort study compared telaprevir-based triple therapy (T/PR) with PR therapy. The study population comprised patients with genotype 1 chronic hepatitis C represented in the database between December 2009 and August 2015. The primary endpoint was dropout from treatment due to adverse events during the relevant standard treatment duration based on guidelines from the Japan Society of Hepatology...
February 9, 2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28179578/socs3-genetic-variants-and-promoter-hypermethylation-in-patients-with-chronic-hepatitis-b
#19
Nghiem Xuan Hoan, Hoang Van Tong, Dao Phuong Giang, Bui Khac Cuong, Nguyen Linh Toan, Heiner Wedemeyer, C Thomas Bock, Peter G Kremsner, Le Huu Song, Thirumalaisamy P Velavan
The clinical manifestations of hepatitis B viral infection (HBV) include chronic hepatitis B (CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). The contribution of negative regulator suppressor of cytokine signaling-3 (SOCS3) promoter variants in HBV disease and SOCS3 hypermethylation in tumor tissues were investigated. The SOCS3 promoter region was screened for polymorphisms in 878 HBV patients and in 272 healthy individuals. SOCS3 promoter methylation was examined by bisulfite sequencing. SOCS3 mRNA expression was quantified in 37 tumor and adjacent non-tumor liver tissue specimens...
February 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28178174/real-world-experience-with-interferon-free-direct-acting-antiviral-therapies-in-asian-americans-with-chronic-hepatitis-c-and-advanced-liver-disease
#20
Christine Y Chang, Pauline Nguyen, An Le, Changqing Zhao, Aijaz Ahmed, Tami Daugherty, Gabriel Garcia, Glen Lutchman, Radhika Kumari, Mindie H Nguyen
Real-life data on interferon (IFN)-free direct acting antiviral (DAA) therapies for chronic hepatitis C (CHC) is limited for Asian Americans.To evaluate sustained virologic response (SVR) and adverse events (AE) in Asian Americans treated with sofosbuvir (SOF)-based, IFN-free DAA therapies.This is a retrospective study of 110 consecutive Asian Americans with HCV genotypes 1 to 3 or 6 treated with IFN-free SOF-based regimens for 8 to 24 weeks between February 2014 and March 2016 at a university center in Northern California...
February 2017: Medicine (Baltimore)
keyword
keyword
85439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"